San Diego, CA., August 24, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers, announced today that the company will be presenting a corporate overview at an upcoming investor conference and attending an industry event for medical devices.
BIOCOM Device Fest 2011
Costa Mesa, CA, August 25
Westin South Coast Plaza
Southern California Investor Conference
Newport Beach, CA, August 29
The Island Hotel
OncoSec Medical Presentation
Michael Cross, Ph.D., Chief Business Officer
About OncoSec Medical Inc.
OncoSec Medical (OTCBB: ONCS) develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.